Colon Cancer Clinical Trial

Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study

Summary

This study will be a prospective analysis conducted by Geneoscopy Inc. to evaluate the ColonoSight test, which is a multi-target stool RNA test for colorectal screening.

View Full Description

Full Description

Patients who are eligible for a colonoscopy (i.e., average risk individuals 45 years of age and older who are not up-to-date with screening guidelines) will be enrolled in the study. Stool samples returned to Geneoscopy's Laboratories by the participant will be subjected to the Colosense test system, and a result will be generated. The result will be compared to an optical colonoscopy to determine: 1) sensitivity for colorectal cancer, advanced adenomas, and other precancerous adenomas and 2) specificity for hyperplastic polyps and no findings on a colonoscopy. This study will be used for the clinical validation of the Colosense test.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subject is male or female, >45 years of age
Subject is able to understand the study procedures, and is able to provide consent to participate in the study and authorizes release of relevant protected health information through reviewing and consenting to a HIPAA medical release form
Subject is able and willing to provide stool samples within the 120 days prior to a colonoscopy procedure.
Subject is able and willing to undergo a colonoscopy after providing a stool sample

Exclusion Criteria:

Subject had any precancerous findings on most recent colonoscopy. This does not include benign, and/or hyperplastic polyps of any size (Note: Tissue biopsies that result in no histopathology findings are acceptable)
Subject has a history or diagnosis of colorectal cancer
Subject has a history of aerodigestive tract cancer

Subject has had a positive non-invasive screening diagnostic within the associated recommended intervals

Fecal occult blood test or fecal immunochemical test within the previous twelve (12) months
FIT-DNA test within the previous 36 months
Subject has had a colonoscopy in the previous nine (9) years.
Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease
Indication for colonoscopy was due to overt rectal bleeding, e.g., hematochezia or melena, within the previous 30 days. (Blood on toilet paper, after wiping, does not constitute rectal bleeding)

Subject has a diagnosis or personal history of any of the following high-risk conditions for colorectal cancer:

Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease
Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP)
Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" of "Lynch Syndrome")
Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis

Study is for people with:

Colon Cancer

Estimated Enrollment:

8000

Study ID:

NCT04739722

Recruitment Status:

Active, not recruiting

Sponsor:

Geneoscopy, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Geneoscopy, Inc.
Saint Louis Missouri, 63146, United States
Elligo Health Research
Austin Texas, 78738, United States

How clear is this clinincal trial information?

Study is for people with:

Colon Cancer

Estimated Enrollment:

8000

Study ID:

NCT04739722

Recruitment Status:

Active, not recruiting

Sponsor:


Geneoscopy, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.